437 related articles for article (PubMed ID: 16179496)
1. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
2. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
3. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
[TBL] [Abstract][Full Text] [Related]
4. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene.
Yeh A; Wei M; Golub SB; Yamashiro DJ; Murty VV; Tycko B
Genes Chromosomes Cancer; 2002 Oct; 35(2):156-63. PubMed ID: 12203779
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
6. Genomic imprinting and Wilms' tumor.
Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of imprinted genes in Wilms tumors.
Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
[TBL] [Abstract][Full Text] [Related]
10. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Mummert SK; Lobanenkov VA; Feinberg AP
Genes Chromosomes Cancer; 2005 Jun; 43(2):155-61. PubMed ID: 15761865
[TBL] [Abstract][Full Text] [Related]
11. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
15. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
16. Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation.
Sullivan MJ; Taniguchi T; Jhee A; Kerr N; Reeve AE
Oncogene; 1999 Dec; 18(52):7527-34. PubMed ID: 10602511
[TBL] [Abstract][Full Text] [Related]
17. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.
Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP
Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665
[TBL] [Abstract][Full Text] [Related]
18. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
19. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
